We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Evotec Announces Progress in Strategic Neuroscience Partnership With Bristol Myers Squibb

A 3D model of a human brain with coloured string emitting from the sides.
Credit: iStock.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research.


Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases where there remains a significant unmet medical need for therapies that slow down or reverse disease progression. The progress announced here leverages Evotec’s PanOmics platform in conjunction with patient-derived disease models, which is one of the largest and most sophisticated platforms in the industry.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

The partnership has generated a promising pipeline of discovery to clinical-stage programmes. A first programme, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021 as BMS-986419. In March 2023, Bristol Myers Squibb and Evotec extended and expanded their partnership for an additional 8 years.


Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: “The achieved milestone underlines the productive nature of our neuroscience partnership with Bristol Myers Squibb. Using our PanOmics-driven drug discovery platform we are targeting neurodegenerative diseases with tremendous unmet medical need. Beyond BMS-986419, we are very excited to advance yet another programme towards the clinic development in 2026.”